CEO of Lpath, 2005-14, took from incubation at SDSU to NASDAQ listing, raised $90M equity, $50M non dilutive capital, partnered with Merck, Pfizer, J&J & Biogen. On DermTech Board (2012-2021), helping CEO grow from raw startup to Nasdaq listing and $1B+ market cap. EVP of WSIG 1994-04, managed portfolio of startups, incl. Endonetics (sold to Medtronic), Mpex (sold to Allergan), Vaxiion (in Ph.1). BA-UVA summa cum laude; MBA-Harvard (honors)

Dr. Blankenship is an emergency MD w/ healthcare startup experience. Most recently, he was Chair of Emergency Services at a large health system. He previously served as Medical Director of Lucidity Direct, a start-up technology platform; did product dev. work at Bard; served as an Associate at the Lassonde New Venture Dev. Center, evaluating novel biotechnologies. Degrees: BA--UVA, MD--U of South Alabama, MBA--UNC Chapel Hill.

Charles (a CPA) started at Bain & Company and Bain Capital. He was then CFO+CEO of an automotive foundry (1985-2015), which he grew from $4M to $50M before selling it to a P/E firm. He then became CFO+CEO of an equip. mfr., diversifying its product offering via a startup company that developed a breakthrough technology in oilfield pipe handling. Degrees: BS--W&L (summa cum laude); MBA-Harvard (Baker Scholar).

Dr. Draganski completed his Ph.D. at Rutgers and then joined Dr. Joel Friedman's laboratory at Albert Einstein College of Medicine; there, he worked on the advancement of the lab's novel drug-delivery platform, becoming the primary inventor of the company’s Z-pod™ delivery platform.

Chris Mann joined Zylö 1/2020 w/ the aim of scaling up the Z-pod™ delivery technology. He's a veteran of another high-tech startup, Plextronics, as well as specialty materials maker Chase Corporation), a paint/coatings mfr Valspar & 3M. He has led scale-up efforts in multiple industries and has valuable experience in design, construction mgmt, and startup/operation of new facilities. Degrees: BS in Chemical Engineering/Chemistry--Penn State

For ~20 years, Mr. Rabin was lead producer at a boutique Investment Bank doing M&A of OTC/cosmetic brands.
Previously with Goldman Sachs and a management consulting firm.
BS economics-U. of Chicago; MBA-Harvard

Dr. Burns has extensive experience in FDA-regulated mfg, R&D, BD, licensing, M&A, At Ferndale Pharma Group (1993-2020), he was President and COO; Ferndale makes and markets Rx and non-Rx dermatological products. Previously, he was CEOof Repromedix, specializing in male and female infertility diagnostics. He is also on the board of SciTech, which develops cancer drugs. Degrees: B.Sc. (Honors)--U of Reading; Ph.D. in Pharmacology--U. of Cambridge